Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
4'-Thio-2'-Deoxycytidine (TdCyd)
i
Other names:
TdCyd
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Company:
National Cancer Institute
Drug class:
DNA methylation inhibitor
Related drugs:
‹
EPI01 (1)
recombinant methionine α, γ-lyase (0)
EPI01 (1)
recombinant methionine α, γ-lyase (0)
›
Associations
(4)
News
Trials
VERI cancer hierarchy
Reset Filters
TET2 deletion + DNMT3A mutation
Melanoma
TET2 deletion + DNMT3A mutation
Melanoma
TdCyd
Sensitive: D – Preclinical
TdCyd
Sensitive
:
D
TdCyd
Sensitive: D – Preclinical
TdCyd
Sensitive
:
D
TET2 deletion + DNMT3A mutation
Kidney Cancer
TET2 deletion + DNMT3A mutation
Kidney Cancer
TdCyd
Sensitive: D – Preclinical
TdCyd
Sensitive
:
D
TdCyd
Sensitive: D – Preclinical
TdCyd
Sensitive
:
D
TET2 deletion + DNMT3A mutation
Lung Cancer
TET2 deletion + DNMT3A mutation
Lung Cancer
TdCyd
Sensitive: D – Preclinical
TdCyd
Sensitive
:
D
TdCyd
Sensitive: D – Preclinical
TdCyd
Sensitive
:
D
TET2 deletion + DNMT3A mutation
Breast Cancer
TET2 deletion + DNMT3A mutation
Breast Cancer
TdCyd
Sensitive: D – Preclinical
TdCyd
Sensitive
:
D
TdCyd
Sensitive: D – Preclinical
TdCyd
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.